MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahjo.2026.100721

Медицинская библиотека · American heart journal plus : cardiology research and practice · 2026

Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.

Greene Stephen J, Michel Alexander, Lecomte Coralie, Manca Paolo, Holl Katsiaryna, Senni Michele

СтатьяПеревод пока не подготовлен

Аннотация

STUDY

OBJECTIVE

To evaluate the following among new users of vericiguat: up-titration patterns, factors associated with up-titration, occurrence of hypotension/syncope, predictors of hypotension/syncope.

DESIGN

Retrospective cohort study (linked claims and electronic health record data).

SETTING

US clinical practice.

PARTICIPANTS

1361 new users of vericiguat.

INTERVENTIONS: N/A.

MAIN OUTCOME MEASURES: Vericiguat starting dose, up-titration patterns and predictors, occurrence and predictors of hypotension/syncope, over a 3-month follow-up period.

RESULTS

Among 1361 new users of vericiguat, 770 (57%) initiated a starting dose of 2.5 mg/day, 330 (24%) initiated a dose of 5 mg/day, and 261 (19%) initiated a dose of 10 mg/day. Over 3-month follow-up, the 10 mg target dose was reached by 349 (26%) patients. Among these patients, the median time to reach the 10 mg dose was 60 days among 2.5 mg/day starters, and 41 days among 5 mg/day starters. Among the 2.5 mg starters, 68% had no up-titration. Among patients initiating either the 2.5 mg/day or 5 mg/day dose, a starting dose of 5 mg (vs. 2.5 mg) was the only significant predictor for reaching the 10 mg dose; adjusted hazard ratio 2.89 (95% CI: 1.86, 4.49, p < 0.0001). Overall, 130 patients (9.6%) had a hypotension event and 67 patients (4.9%) had a syncope event. History of hypotension was the strongest independent predictor of hypotension/syncope events (adj. HR 2.85, 95% CI: 1.96, 4.13, p < 0.0001). A > 2.5 mg/day vericiguat starting dose was not associated with the occurrence of hypotension/syncope (vs. 2.5 mg/day); adj. HR 0.82, 95% C.I. (0.58, 1.16).

CONCLUSION

Vericiguat users initiated on the 5 mg/day dose were considerably more likely to reach the target dose of 10 mg/day vs. those started on the recommended 2.5 mg/day dose, without excess risk of hypotension or syncope.

Для цитирования: Greene Stephen J, Michel Alexander, Lecomte Coralie, Manca Paolo, Holl Katsiaryna, Senni Michele. Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.. American heart journal plus : cardiology research and practice. 2026. DOI: 10.1016/j.ahjo.2026.100721.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.